MARKET

OASMY

OASMY

Vivesto
EXMKT

Real-time Quotes | Nasdaq Last Sale

0.197
0.000
0.00%
Closed 16:00 08/12 EDT
OPEN
--
PREV CLOSE
0.197
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
1.223
52 WEEK LOW
0.197
MARKET CAP
32.69M
P/E (TTM)
-6.0367
1D
5D
1M
3M
1Y
5Y
BRIEF-Oasmia Signs Manufacturing Agreement With Lonza For Ovarian Cancer Drug Candidate Cantrixil
reuters.com · 03/21 08:07
Lonza signs manufacturing agreement with Oasmia for ovarian cancer drug
reuters.com · 03/21 06:11
Kazia Therapeutics Licenses Cantrixil To Oasmia Pharmaceutical For Ovarian Cancer
Kazia Therapeutics Ltd (NASDAQ: KZIA) has 
Benzinga · 03/01/2021 13:39
Kazia grants global rights for ovarian cancer therapy to Oasmia
Kazia Therapeutics (KZIA) has granted worldwide exclusive rights to develop and commercialize Cantrixil (TRX-E-002-1) to Oasmia Pharmaceutical AB (OASMY) targeting all indications, with an initial focus on ovarian cancer.Under the terms of
Seekingalpha · 03/01/2021 12:20
No Data
Learn about the latest financial forecast of OASMY. Analyze the recent business situations of Vivesto through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
EPS
Actual
Estimate
0.000.010.030.04
Q4 2020
Q1 2021
Q2 2021
Q3 2021
    0
Q4 2021
Institutional Holdings
Institutions: 4
Institutional Holdings: 38.63K
% Owned: 0.02%
Shares Outstanding: 165.58M
TypeInstitutionsShares
Increased
0
0
New
1
2.60K
Decreased
2
907
Sold Out
5
45.74K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+1.44%
Pharmaceuticals & Medical Research
+1.45%
Key Executives
Chairman/Director
Julian Aleksov
Chief Executive Officer
Mikael Asp
Chief Financial Officer/Executive Vice President
Anders Blom
Chief Accounting Officer
Magdalena Berg
Other
Dzianis Babrou
Other
John Cosby
Other
Nina Heldring
Other
Henrik Ronnberg
Director
Bo Cederstrand
Director
Per Lango
Independent Director
Lars Bergkvist
Independent Director
Alexander Kotsinas
No Data
No Data
About OASMY
Oasmia Pharmaceutical AB is a Sweden-based pharmaceutical company dedicated to improving the lives of patients by enhancing the intravenous delivery of drugs in diseases such as cancer. Product development is based on Oasmia’s drug delivery platform which can be applied to medicines used in many therapeutic areas, to develop water soluble formulations of drugs that usually require chemical solubilizers for dissolution. The Company's approved product that is using this technology is Apealea (paclitaxel micellar). Apealea has market authorization in the European Union and several other territories for the treatment of first relapse in platinum-sensitive ovarian cancer, in combination with carboplatin. The Company is making Apealea accessible to patients through its partnership with Elevar Therapeutics, together with its existing commercial operations in the Nordic region.

Webull offers kinds of Oasmia Pharmaceutical AB stock information, including EXMKT:OASMY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OASMY stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading OASMY stock methods without spending real money on the virtual paper trading platform.